Eisai Corporation of North America Release: FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)
7/8/2009 8:07:04 AM
More...
|
Eisai Corporation of North America and Pfizer Inc. (PFE) Decide not to Appeal NICE Decision and Call for an Expedited Review of Guidance for Alzheimer's Disease
7/1/2009 7:08:09 AM
More...
|
Morphotek Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
3/23/2009 7:29:44 AM
More...
|
FDA Approves Eisai Corporation of North America's LUSEDRA(TM) Injection for Monitored Anesthesia Care (MAC) Sedation
12/15/2008 6:30:59 AM
More...
|
FDA Approves Eisai Corporation of North America's BANZEL(TM) (rufinamide) as Adjunctive Treatment for Severe Epilepsy Disorder
11/17/2008 6:58:56 AM
More...
|
Morphotek Inc. Expands Its Phase II Trial Site Selections in the European Union
8/26/2008 8:06:43 AM
More...
|
FDA Approves Eisai Corporation of North America's ALOXI(R) Capsules for Prevention of Acute Chemotherapy-induced Nausea and Vomiting
8/25/2008 7:10:59 AM
More...
|
Morphotek Inc. Announces License Agreement for the Development of a Monoclonal Antibody to Treat Prostate Cancer
8/13/2008 8:43:16 AM
More...
|
Eisai Corporation of North America Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures; FDA's Not Approvable Letter Outlines Pathway to Potential Approval
7/28/2008 6:18:24 AM
More...
|
Eisai Corporation of North America Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
7/2/2008 7:11:59 AM
More...
|
|